BOSTON, Oct. 14 /PRNewswire/ -- Surface Logix, a privately held
biopharmaceutical company focused on using biophysical chemistry to create
and develop novel small molecule drugs, is pleased to announce the
appointment of Keith Dionne, Ph.D. to the position of President and Chief
Executive Officer and to its Board of Directors. Dr. Dionne is a seasoned
executive with nearly 20 years of leadership experience in the
biotechnology industry.
"We are delighted to welcome Keith at this important stage of Surface
Logix's development," stated Steven Gillis, Ph.D., Managing Director at
ARCH Venture Partners and Chairman of Surface Logix. "We are confident that
his proven track record and depth of experience will be instrumental as the
Company continues to make progress on a number of fronts, including the
further clinical development of two candidates in Phase 2 clinical trials."
Dr. Dionne was previously CEO of Alantos Pharmaceuticals, where he led
the Company through a successful acquisition by Amgen for more than $300
million in cash. Prior to Alantos, Dr. Dionne held senior-level positions
at Millennium Pharmaceuticals, including most recently Vice President of
Research and Development Strategy and Vice President & General Manager:
Technology Business. Before his 7-year tenure at Millennium, Dr. Dionne
provided scientific leadership at ALZA Pharmaceuticals as Head of
Pre-Clinical Research & Development: Implants.
"Surface Logix appealed to me because of its mature, differentiated
pipeline, its exciting discovery capabilities and the strong team of
discovery and development professionals," said Dr. Dionne. "I look forward
to working with this team and our experienced Board and investors to fully
realize the value of Surface Logix's late stage clinical assets and our
discovery engine."
Dr. Dionne earned both his Ph.D. in Chemical Engineering and his M.S.
in the Program for Technology Policy from the Massachusetts Institute of
Technology and has served as an Adjunct Professor in the Biomedical
Department at Brown University. Dr. Dionne was also one of four original
scientists at CytoTherapeutics, Inc., a cell transplantation company.
About Surface Logix Inc.
Surface Logix Inc. uses its expertise in biophysical chemistry to
create and develop novel small molecule drugs (NCEs) that target the
gastrointestinal tract or the cardiovascular system. The Company is
advancing multiple internal programs in the areas of metabolic,
cardiovascular and other diseases. For more information, please visit
http://www.surfacelogix.com.
Contact:
Leland Webster, Ph.D., M.B.A.
Surface Logix Inc.
Vice President, Corporate Development
617.746.8520
Media:
Sarah Cavanaugh
MacDougall Biomedical Communications Inc.
scavanaugh@macbiocom.com
781.235.3060
|
